With antimicrobial resistance rising as one of the world's most pressing health threats, the 8th World Congress on Targeting ...

Biliary tract infections (BTI), often linked to structural abnormalities like bile duct stones, pose significant treatment challenges due to drug-resistant bacteria like Pseudomonas aeruginosa. Phage ...

In the fight against antimicrobial-resistant (AMR) superbugs, an important weapon may just be hiding in some polluted stream, ...

The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...

Returning to Boston this February, the Bacteriophage Therapy Summit is the only global platform for industry-dominated phage drug developers. Uniting 90+ Chief Executive Officers, Vice Presidents ...

pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and ...

BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at ...

NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...

FMT is a novel therapeutic approach that involves transferring microbiota from a healthy donor to a patient's ...

Armata Pharmaceuticals, Inc.’s ARMP share price has dipped by 10.63%, which has investors questioning if this is right time to buy.

In a growing global trend, bacteria are evolving new ways to maneuver around medical treatments for a variety of infections.

Gene editing and many other useful biotechnology tools came from studies of bacteria fighting off viral invaders. But ...